Covidien pursues $3B share buyback; Hologic unloads business line for $85M;

 @FierceMedDev: Cornell: Metal stents work well as blocked bile duct treatment. Item | Follow @FierceMedDev

 @MarkHFierce: Third Rock is rolling out a new $516M VC fund, for device, Dx and biotech companies. Target: early-stage companies. Release | Follow @MarkHFierce

 @DamianFierce: Abbott is warning overseas surgeons about a safety issue with MitraClip, all as it seeks FDA approval. Report | Follow @DamianFierce

> Covidien ($COV) will launch a new effort to buy back up to $3 billion of its shares, on top of a $2 billion share repurchase program under way since August 2011. Release

> Hologic ($HOLX), a maker of diagnostics, medical imaging systems and surgical tools focused on women, has completed the $85 million sale of its LIFECODES business to Immucor. Item

> Cambridge Cognition, a maker of neuropsychological diagnostic tests, will pursue an IPO in the U.K. Story

> CardioDx, a 2012 Fierce 15 company, generated promising data in a recent trial that showed its Corus CAD was more accurate in diagnosing obstructive coronary artery disease in women than evaluation of symptoms and myocardial perfusion imaging. Release

> SQI Diagnostics has completed a proof of concept test for two forms of heparin using its signature diagnostic tech. Item

> ConservoCare, a startup spun off from Case Western Reserve University, is developing a nerve stimulation device that helps treat bladder-control problems. Story

Biotech News

 @FierceBiotech: More on CRO shutdown from Former Cetero shutters ops, leaving sponsors, patients locked out. Story | Follow @FierceBiotech

@JohnCFierce: Third Rock Ventures adds $516M fund to back new portfolio of biotechs. News | Follow @JohnCFierce

@RyanMFierce: Astellas Pharma taps supercomputer for IT-driven drug discovery. More | Follow @RyanMFierce

> Versant adds $7.5M to upstart biotech's A round. Story

> Strike two: FDA hands United Therapeutics another rejection on oral Remodulin. Article

> Novartis snags FDA approval for antibiotic in CF patients. Story

Pharma News

@FiercePharma: Interesting look at Big Pharma's new-drug sales, a.k.a Freshness Index, from Forbes columnist Bernard Munos. Report | Follow @FiercePharma

@EricPFierce: Actavis getting nearly $3 million from taxpayers to expand a plant in Florida. Story | Follow @EricPFierce

> Drugmakers on edge as pay-for-delay case hits Supreme Court. Item

> Early copies of Sanofi's Aubagio could roil European MS market. Article

> AstraZeneca zaps another Crestor generic threat with Actavis settlement. News

CRO News

> Bayer deepens Cambodian presence with DKSH partnership. More

> Sanofi beefs up CMO game with Transgene deal. Item

> Dr. Reddy's wins $22.5M from CRO Nordion. News

> Duke's in-house CRO snags trial deal for RNAi drug. Article

> ShangPharma wins investor vote for go-private plan. Story

Biotech IT News

> BlackBerry founder bets on quantum tech in life sciences. Item

> NextDocs and Microsoft pushing clinical trials to the cloud. Story

> AstraZeneca IT chief talks up Big Data amid R&D turmoil. Report

> Biotech data merges onto UC San Diego's Big Data "freeway." Article

> Merck slashes data-management costs with China site. More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.